The development of inflammatory arthritis in patients receiving immune checkpoint inhibitor therapy is increasingly recognized due to the growing use of these drugs for the treatment of cancer. This represents an important opportunity not only to define the mechanisms responsible for the development of this immune-related adverse event and to ultimately predict or prevent its development, but also to provide a unique window into early events in the development of inflammatory arthritis. Knowledge gained through the study of this patient population, for which the inciting event is known, could shed light into the pathogenesis of autoimmune arthritis. This review will highlight the clinical and immunologic features of these entities to define common elements for future study.
Keywords: autoimmunity; cancer; immune checkpoint inhibitor; immune-related adverse event; rheumatoid arthritis; spondyloarthropathy.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.